Last updated: 18 July 2019 at 8:51pm EST

Marc E. Goldberg Net Worth




The estimated Net Worth of Marc E. Goldberg is at least $1.71 Million dollars as of 6 December 2013. Marc Goldberg owns over 6,861 units of CohBar Inc stock worth over $235,471 and over the last 12 years Marc sold CWBR stock worth over $1,479,128.

Marc Goldberg CWBR stock SEC Form 4 insiders trading

Marc has made over 2 trades of the CohBar Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Marc sold 6,861 units of CWBR stock worth $191,628 on 6 December 2013.

The largest trade Marc's ever made was selling 50,000 units of CohBar Inc stock on 26 November 2013 worth over $1,287,500. On average, Marc trades about 14,215 units every 3 days since 2013. As of 6 December 2013 Marc still owns at least 547,606 units of CohBar Inc stock.

You can see the complete history of Marc Goldberg stock trades at the bottom of the page.



What's Marc Goldberg's mailing address?

Marc's mailing address filed with the SEC is C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN, MA, 02472.

Insiders trading at CohBar Inc

Over the last 7 years, insiders at CohBar Inc have traded over $0 worth of CohBar Inc stock and bought 586,523 units worth $136,480 . The most active insiders traders include Misha Petkevich, Kenneth C Cundy, and Jon Leland Stern. On average, CohBar Inc executives and independent directors trade stock every 22 days with the average trade being worth of $9,727. The most recent stock trade was executed by David Greenwood on 1 November 2021, trading 20,000 units of CWBR stock currently worth $8,600.



What does CohBar Inc do?

cohbar (otcqx: cwbr and tsxv: cob.u) is the leader in the research and development of mitochondria-based therapeutics (mbts), an emerging class of drugs for the treatment of diseases associated with aging. mbts originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. this groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. mbts offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.



Complete history of Marc Goldberg stock trades at Enanta Pharmaceuticals Inc and CohBar Inc

Insider
Trans.
Transaction
Total value
Marc E. Goldberg
Director
Sale $191,628
6 Dec 2013
Marc E. Goldberg
Director
Sale $1,287,500
26 Nov 2013


CohBar Inc executives and stock owners

CohBar Inc executives and other stock owners filed with the SEC include: